Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2025 16:30 ET | Source: ProQR Therapeutics N.V.

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted...
May 13, 2025 08:00 ET | Source: Remedy Plan Therapeutics

Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials

Remedy Plan has raised an $18M insider round to advance their lead asset, RPT1G, into a Phase 1/2 clinical trial in patients with AML and high-risk MDS
December 18, 2024 08:30 ET | Source: Remedy Plan Therapeutics

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor